Title |
Acute dosing of latrepirdine (Dimebon™), a possible Alzheimer therapeutic, elevates extracellular amyloid-β levels in vitro and in vivo
|
---|---|
Published in |
Molecular Neurodegeneration, December 2009
|
DOI | 10.1186/1750-1326-4-51 |
Pubmed ID | |
Authors |
John W Steele, Soong H Kim, John R Cirrito, Deborah K Verges, Jessica L Restivo, David Westaway, Paul Fraser, Peter St George Hyslop, Mary Sano, Ilya Bezprozvanny, Michelle E Ehrlich, David M Holtzman, Sam Gandy |
Abstract |
Recent reports suggest that latrepirdine (Dimebon, dimebolin), a retired Russian antihistamine, improves cognitive function in aged rodents and in patients with mild to moderate Alzheimer's disease (AD). However, the mechanism(s) underlying this benefit remain elusive. AD is characterized by extracellular accumulation of the amyloid-beta (Abeta) peptide in the brain, and Abeta-lowering drugs are currently among the most popular anti-amyloid agents under development for the treatment of AD. In the current study, we assessed the effect of acute dosing of latrepirdine on levels of extracellular Abeta using in vitro and in vivo experimental systems. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 2% |
Belgium | 1 | 2% |
Canada | 1 | 2% |
Unknown | 51 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 14 | 26% |
Student > Master | 9 | 17% |
Student > Ph. D. Student | 6 | 11% |
Student > Bachelor | 6 | 11% |
Professor | 4 | 7% |
Other | 9 | 17% |
Unknown | 6 | 11% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 15 | 28% |
Neuroscience | 10 | 19% |
Biochemistry, Genetics and Molecular Biology | 7 | 13% |
Chemistry | 4 | 7% |
Medicine and Dentistry | 4 | 7% |
Other | 7 | 13% |
Unknown | 7 | 13% |